Literature DB >> 31477222

DOACS in women: pros and cons.

Jan Beyer-Westendorf1.   

Abstract

The recent approval of direct-acting oral anticoagulants (DOAC) for long-term anticoagulation in atrial fibrillation and venous thromboembolism resulted in a rapid implementation of these new drugs into daily care. Although DOAC dosing is similar for women and men and, overall, results in comparable outcomes, sex specific issues need to be considered. This review will discuss DOAC topics specifically related to women's health, including the risks and benefits of DOAC treatment for women, the issue of abnormal uterine bleeding from DOAC and the risk and management of DOAC exposure in pregnancy.
© 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abnormal uterine bleeding; DOAC; Direct oral anticoagulants; Menorrhagia; Pregnancy

Mesh:

Substances:

Year:  2019        PMID: 31477222     DOI: 10.1016/S0049-3848(19)30361-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Direct oral anticoagulants for unusual-site venous thromboembolism.

Authors:  Nicoletta Riva; Walter Ageno
Journal:  Res Pract Thromb Haemost       Date:  2021-01-28

Review 2.  Special Considerations for Women of Reproductive Age on Anticoagulation.

Authors:  Tali Azenkot; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2022-05-31       Impact factor: 6.473

3.  Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.

Authors:  Pamela L Lutsey; Richard F MacLehose; J'Neka S Claxton; Rob F Walker; Terrence J Adam; Alvaro Alonso; Neil A Zakai
Journal:  Vasc Med       Date:  2020-07-27       Impact factor: 3.239

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.